Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Código QR

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Maju Mathews,1 Srihari Gopal,2 Arun Singh,3 Isaac Nuamah,4 Katalin Pungor,5 Wilson Tan,6 Bernardo Soares,7 Edward Kim,8 Adam J Savitz2 1Global Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA; 2Department of Neuroscience, Janssen Research & Development, LLC,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	long-acting injectables relapse prevention schizophrenia oral paliperidone extended release paliperidone palmitate once monthly paliperidone palmitate three monthly Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f4725d040b5f44bab2cab8cb43f06574
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal S, et al.
Publicado: (2020)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
por: Natalia N. Petrova, et al.
Publicado: (2020)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz WF, et al.
Publicado: (2020)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz AJ, et al.
Publicado: (2017)

Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics
por: Radha-Rani Earle, et al.
Publicado: (2021)

Validation of a quick and simple chromatographic method for simultaneous quantification of sertraline, escitalopram, risperidone and paliperidone levels in the human plasma
por: Jeremić Aleksandra, et al.
Publicado: (2021)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang H, et al.
Publicado: (2016)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen CY, et al.
Publicado: (2018)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas A, et al.
Publicado: (2017)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi C, et al.
Publicado: (2016)

Comparison of Weight Gain in Injectable Contraceptive 1-Month And 3-Month Acceptors at The Independent Midwife Practice Tambaksari Surabaya
por: Khoiriya Ardiani, et al.
Publicado: (2020)

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study
por: Kiss Alexander
Publicado: (2018)

An examination of short-run performance of IPOs using Extreme Bounds Analysis
por: Mumtaz,Muhammad Zubair, et al.
Publicado: (2016)

Influence of long-chain fatty acids on weight gain of Hylastinus obscurus (Coleoptera: Curculionidae)
por: Toledo,Dayand, et al.
Publicado: (2014)

Effect of nitrogen on achene protein, oil, fatty acid profile, and yield of sunflower hybrids
por: Ali,Amjed, et al.
Publicado: (2012)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
por: Savitz AJ, et al.
Publicado: (2019)

Comparison of Gridded and Measured Rainfall Data for Basin-scale Hydrological Studies
por: Muñoz,Enrique, et al.
Publicado: (2011)

Hubungan Pemberian ASI Eksklusif Terhadap Perkembangan Bayi Usia 6-9 Bulan di Desa Podosoko Kecamatan Sawangan Kabupaten Magelang Tahun 2013
por: Siti Fadhilah, et al.
Publicado: (2014)

Effects of palmitic acid and eicosapentaenoic acid on angiogenesis of porcine vascular endothelial cells
por: Jie Peng, et al.
Publicado: (2021)

A Novel Decomposition and Combination Technique for Forecasting Monthly Electricity Consumption
por: Xi Zhang, et al.
Publicado: (2021)

Efektifitas Penggunaan Virgin Coconut Oil (VCO) Terhadap Pencegahan Diaper Rash pada Bayi Usia 1-12 Bulan di Wilayah Kerja Puskesmas Depok II Sleman
por: Jennifa Jennifa, et al.
Publicado: (2014)

Mechanisms Driving Palmitate-Mediated Neuronal Dysregulation in the Hypothalamus
por: Calvin V. Lieu, et al.
Publicado: (2021)

Ascorbyl palmitate/d-α-tocopheryl polyethylene glycol 1000 succinate monoester mixed micelles for prolonged circulation and targeted delivery of compound K for antilung cancer therapy in vitro and in vivo
por: Zhang Y, et al.
Publicado: (2017)

Palmitic acid causes increased dihydroceramide levels when desaturase expression is directly silenced or indirectly lowered by silencing AdipoR2
por: Mario Ruiz, et al.
Publicado: (2021)

Extraction and Discrimination of MBT Anomalies Possibly Associated with the Mw 7.3 Maduo (Qinghai, China) Earthquake on 21 May 2021
por: Yuan Qi, et al.
Publicado: (2021)

Salubrinal abrogates palmitate-induced leptin resistance and endoplasmic reticulum stress via nuclear factor kappa-light-chain-enhancer of activated B cell pathway in mHypoE-44 hypothalamic neurons
por: Zhang M, et al.
Publicado: (2018)